Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T6RG
|
|||
| Former ID |
DNCL003741
|
|||
| Drug Name |
SAR113244
|
|||
| Synonyms |
LPA-1/LPA-3
Click to Show/Hide
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 1 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C chemokine receptor type 5 (CXCR5) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02321709) Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.